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Edited by Stuart FergusonAbstract The AcrB of Escherichia coli pumps out a wide range
of compounds, including most of the currently available antibiot-
ics, and contributes signiﬁcantly to the serious problem of multi-
drug resistance of pathogenic bacteria. Quantitative analysis of
drug eﬄux by this pump requires the measurement of the aﬃnity
of ligands. Yet there has been no success in determining these
values. We introduce here an approach of steady-state ﬂuores-
cence polarization to study the interactions between four diﬀer-
ent ligands and the puriﬁed AcrB transporter in a detergent
environment. Our assays indicate that the transporter binds these
drugs with KD values ranging from 5.5 to 74.1 lM.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The emergence of multidrug-resistant pathogenic bacteria is
a major current problem in public health. In gram-negative
bacteria, much of the multidrug resistance phenotype is caused
by the increased expression of multidrug eﬄux pumps. These
pumps fall into several families, small multidrug resistance
(SMR), major facilitator superfamily (MFS), multidrug and
toxic compound extrusion (MATE), and resistance-nodula-
tion-division (RND). The members of the RND superfamily
[1] pump out the widest range of compounds, and are usually
the major contributor to both the intrinsic antibiotic resis-
tance, and when overexpressed, the increased resistance levels
of multidrug resistant strains [2], as was recognized already
in 1993 [3] and 1994 [4]. However, quantitative analysis of
the function of RND eﬄux pumps could not even be at-
tempted during the last 14 years, because all attempts to mea-
sure the kinetic constants of the pump resulted in failure.
We here use a relatively simple methodology to quantita-
tively monitor interaction between a membrane protein, which
in this study is the AcrB multidrug eﬄux pump of Escherichia
coli [5], and its ﬂuorescent ligands in detergent solution. Bind-
ing of a ﬂuorescent ligand to a protein causes a decrease in
rotational motion due to an increase in the size of the pro-*Corresponding author. Address: Department of Physics and Astron-
omy, Iowa State University, Ames, IA 50011, United States.
E-mail address: ewyu@iastate.edu (E.W. Yu).
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doi:10.1016/j.febslet.2007.09.035tein–ligand complex as compared to that of the free ligand,
and thus results in increases in the polarization of ﬂuorescence
of the bound ligand. Fluorescence polarization is deﬁned as
P ¼ ðIk  I?Þ=ðIk þ I?Þ
where P is the observed polarization, and Ik and I? represent
the intensity of emissions parallel and perpendicular to the
incident polarized light.
AcrB [5] is a prototypical member of the RND family of
transporters [1]. It recognizes many structurally unrelated
compounds, including most of the currently available antibiot-
ics and chemotherapeutic agents, detergents, dyes, and simple
solvents, and actively engages to extrude them from cells [6].
This inner membrane eﬄux pump interacts with a periplasmic
membrane fusion protein, AcrA [7], and an outer membrane
channel, TolC [8], to mediate the extrusion of toxic compounds
directly into the external medium, across both membranes of
E. coli.
The structure of AcrB has been studied extensively [9–16].
Using the puriﬁed AcrB multidrug eﬄux pump, we succeeded
for the ﬁrst time in determining the aﬃnity of ligands for the
pump, and further in demonstrating the competition between
ligands for the binding process. This study will be the ﬁrst
step for the quantitative analysis of the kinetics of the most
important class of multidrug eﬄux pumps in gram-negative
bacteria.2. Materials and methods
2.1. Puriﬁcation of AcrB
The AcrB protein that contains a 4·His tag at the C-terminus was
overproduced in E. coli BL21-Gold (DE3) cells (Stratagene) using the
plasmid derived from pSPORT1 (Invitrogen) [17]. Cells were grown in
6 L of LB medium with 100 lg/ml ampicillin. Cells were disrupted
with a French pressure cell. The membrane fraction was collected
and washed twice with high salt buﬀer containing 20 mM sodium
phosphate (pH 7.2), 2 M KCl, 10% glycerol, 1 mM EDTA and
1 mM phenylmethanesulfonyl ﬂuoride (PMSF), and once with
20 mM HEPES–NaOH buﬀer (pH 7.5) containing 1 mM PMSF.
The membrane proteins were then solubilized in 1% (w/v) n-dodecyl-
b-D-maltoside (DDM). Insoluble material was removed by ultracentri-
fugation at 370000 · g. The extracted protein was puriﬁed with
hydroxyapatite, Cu2+-aﬃnity and G-200 sizing columns [10,18].2.2. Fluorescence polarization assays
Fluorescence polarization assays [19,20] were used to determine the
drug binding aﬃnities of AcrB. The experiments were done using a li-
gand binding solution containing 20 mM Tris (pH 7.5), 0.05% DDM,
and 1 lM ligand [rhodamine 6G (R6G), ethidium (Et), proﬂavin (Pf),blished by Elsevier B.V. All rights reserved.
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7.5), 0.05% DDM, and 1 lM ligand was titrated into the ligand bind-
ing solution until the polarization (P) became unchanged. In this assay,
the protein–drug interaction would reach equilibrium within 1 min. As
this is a steady-state approach, ﬂuorescence polarization measurement
was taken after incubation for 5 min for each corresponding concen-
trations of the protein and drug to ensure that the binding has reached
equilibrium. It should be noted that the detergent concentration was
kept constant at all times to eliminate the change in polarization gen-
erated by drug–DDM micelle interaction. All measurements were per-
formed at 25 C using a PerkinElmer LS55 spectroﬂuorometer
equipped with a Hamamatsu R928 photomultiplier. The excitation
wavelengths were 527, 483, 447, and 330 nm, respectively, for R6G,
Et, Pf, and Cip. Fluorescence polarization signals (in DP) were mea-
sured at emission wavelengths of 550, 620, 508, and 415 nm, respec-
tively, for these ligands. Each titration point recorded was an
average of 15 measurements. Data were analyzed using the equation,
P ¼ fðP bound  P freeÞ½protein=ðKD þ ½proteinÞg þ P free, where P is the
polarization measured at a given total protein concentration, P free is
the initial polarization of free ligand, P bound is the maximum polariza-
tion of speciﬁcally bound ligand, and [protein] is the protein concentra-
tion. The titration experiments were repeated for three times to
obtained the average KD value. Curve ﬁtting was accomplished using
the program ORIGIN [21].3. Results
3.1. Binding aﬃnities of various AcrB ligands
The goal of this research was to determine the binding aﬃn-
ities of a variety of ligands to AcrB. Fluorescence polarization
based-assay was initially carried out to study the interaction
between AcrB and R6G. Fig. 1a illustrates the binding iso-
therm of AcrB in the presence of 1 lM R6G. As presented
in the ﬁgure, a simple hyperbolic curve was observed with
the KD of 5.5 ± 0.9 lM. The Hill plot of the data (Fig. 1b)
yields a Hill coeﬃcient of 1, suggesting a simple drug binding
process with no cooperativity.
Fluorescence polarization was also used to observe the bind-
ing of Et, Pf and Cip to the transporter. In comparison withFig. 1. Representative ﬂuorescence polarization of AcrB in 0.05%
DDM with R6G. (a) Binding isotherm of AcrB with R6G, showing a
KD of 5.5 ± 0.9 lM, in buﬀer containing 20 mM Tris (pH 7.5) and
0.05% DDM. (b) Hill plot of the data obtained for R6G binding to
AcrB. a corresponds to the fraction of bound R6G. The plot gives a
slope of 1.12 ± 0.02, indicating a simple binding process with a
stoichoimetry of one AcrB protomer per one drug molecule. The
interception of the plot provides a KD of 5.4 ± 1.0 lM for the R6G
binding.R6G, other ligands tested show somewhat lower aﬃnity. Thus,
Et bound with a KD of 8.7 ± 1.9 lM (Fig. 2a), Pf with that of
14.5 ± 1.1 lM (Fig. 2b), and Cip with that of 74.1 ± 2.6 lM
(Fig. 2c).Fig. 2. Fluorescence polarization of AcrB with Et, Pf and Cip. Binding
isotherms of AcrB with (a) Et, showing a KD of 8.7 ± 1.9 lM, (b) Pf,
showing a KD of 14.5 ± 1.1 lM, and (c) Cip, showing a KD of
74.1 ± 2.6 lM.
Fig. 3. Binding of ligands by AcrB in the presence of 100 lM of Et as
determined by ﬂuorescence polarization assay. The change in ﬂuores-
cence polarization signals (DFP) of Pf was measured at an emission
wavelength of 508 nm. The binding curve suggests a KD of 61.0 ±
0.9 lM for Pf.
Fig. 4. Eﬀect of pH on the KD of R6G binding to AcrB. The resulting
KDs were plotted against pH.
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We carried out several titration experiments that involved
the initial saturation of AcrB with 100 lM of Et. To ensure
that AcrB and Et formed a complex, the mixture was incu-
bated for at least 2 h before titrating with 1.5 lM Pf. Fluores-
cence polarization experiments indicated that AcrB-Et binds
Pf with a KD of 61.0 ± 0.9 lM (Fig. 3). This value is about four
times of the KD of Pf (14.5 ± 1.1 lM) in the absence of Et, indi-
cating that Et interferes with the binding of Pf to AcrB, possi-
bly because the two compounds compete with each other for
the same binding site.
We carried out similar titration experiments with the
pre-formed AcrB–Et complex using 1.5 lM Cip. The results
gave a KD value of 70.4 ± 15.4 lM for Cip (data not shown),
which is not signiﬁcantly diﬀerent from the KD of Cip
(74.1 ± 2.6 lM) determined in the absence of Et. Although it
is tempting to conclude that Et and Cip bind to non-overlap-
ping sites, the numerical precision of KD values is not high
in this case because of the quite low aﬃnity of this ligand,
and we believe that further experiments utilizing diﬀerent ap-
proaches are needed in this case.3.3. pH dependence of drug binding to AcrB
We performed ﬂuorescence polarization experiments to
determine the binding of R6G to AcrB at diﬀerent pH values.
Fig. 4 illustrates the decrease in KD values for rhodamine 6G
as the pH increases from 5.5 to 8.4.3.4. Detergent concentration does not aﬀect drug binding to
AcrB
To analyze if the detergent concentration aﬀects the ﬂuores-
cence polarization results, we measured the dissociation con-
stant of the AcrB–R6G complex in diﬀerent concentrations
of detergent, DDM. We found that at moderate detergent con-
centrations, the concentration of detergent does not have much
inﬂuence on the results. At 0.5%, 0.05%, and 0.005% DDM,the dissociation constants of the AcrB–R6G complex were
7.2 ± 0.1, 5.5 ± 0.9, and 4.4 ± 0.8 lM, respectively.4. Discussion
We demonstrated that the technique of ﬂuorescence polari-
zation is sensitive and precise enough to detect ligand binding
of E. coli AcrB, an intrinsic membrane protein in a detergent
environment. As this is a steady-state approach, it is important
to ensure that the binding equilibrium has reached before data
collection. A stop-ﬂow study of an oligopeptide OppA trans-
porter, belonging to the ABC superfamily, indicated that pep-
tide binding to OppA would reach equilibrium within 20 ms
when the concentrations of the protein and peptide are in
the micromolar range [22]. Thus, a 5 min period for incubation
in our experiments should be more than enough to allow the
binding to reach equilibrium. We obtained results showing
that the ligands bind to AcrB with their KD values between
5.5 (R6G) and 74.1 lM (Cip) (Figs. 1 and 2). These values
are similar to the KD for most substrates for the MdfA (a
MFS transporter) [23] and EmrE (a SMR transporter) [24]
multidrug pumps, determined by competition with tetraphe-
nylphosphonium binding. Although our data suggested the
binding stoichiometry of 1:1 monomeric AcrB-to-drug molar
ratio, there is a formal possibility that any compound may
bind to more than one site on the protein with similar aﬃnity
that could not be discriminated using this technique. Thus, fur-
ther experiments utilizing diﬀerent approaches are needed to
conﬁrm this drug binding stoichiometry.
One of the main goals of our work is to introduce a relatively
simple approach to study membrane protein–ligand interac-
tion in a detergent environment. It should be note that deter-
gent solubilized protein in detergent micelles may behave
diﬀerently from that reconstituted in a lipid environment,
including altering the binding aﬃnity of drugs to AcrB in this
case. However, a study of the EmrE transporter suggested that
EmrE binds drugs with similar strengths in diﬀerent membrane
mimetic environments, including those in DDM micelles and
in reconstituted lipid vesicles [25]. The observed dissociation
constants were in the micromolar range for the EmrE drugs
in any of the membrane mimetic environments [25]. Detailed
Fig. 5. AcrB binding competition experiment between R6G and TPP.
AcrB (10 lM) was pre-incubated with R6G (1 lM) for 2 h before
titration. The change in ﬂuorescence polarization signals (DFP) of
R6G was measured at an emission wavelength of 550 nm. TPP was
non-ﬂuorescent in the experimental conditions. The decrease in DFP
showed that the bound R6G was knocked oﬀ by TPP.
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would be necessary to determine whether the reconstituted
AcrB behaves diﬀerently in terms of drug binding aﬃnity.
As our ﬂuorescence polarization assay was performed in a
detergent environment, we aware of the fact that detergent mi-
celles in solution may have interaction with the drug mole-
cules. To eliminate this ‘‘non-speciﬁc’’ binding component
that may cause an error for the measurement of drug binding
aﬃnity, it is important to keep the detergent concentration
constant during titrations. It has been reported that the disso-
ciation constants of DDM micelle with Et and Pf are 5.2 and
17.1 mM, respectively [25]. We measured the binding aﬃnities
of DDM micelle with R6G and Cip using ﬂuorescence polari-
zation assay (data not shown). We found that the interactions
between the micelles and drugs are quite weak. Thus, we could
only estimate these KD values, which were 2.9 mM for R6G–
DDM micelle and 899.7 mM for Cip–DDM micelle, respec-
tively. Apparently, the drug–DDM micelle interactions are in
the millimolar range, which are about three orders of magni-
tude weaker than those of the drug–transporter interactions.
We also examined the question of simultaneous binding of
two diﬀerent drugs to AcrB, by using ﬂuorescence polarization
assays. Et was a convenient ligand because it absorbs and
emits light at very long wavelengths, far away from the wave-
lengths used by other dyes. Titrations of Pf into Et-saturated
AcrB yielded a much increased dissociation constant com-
pared with that in the absence of Et, suggesting strongly that
both drugs bind in a competitive manner to an overlapping
binding site in AcrB.
To conﬁrm that two drugs compete with one another for a
speciﬁc binding site in the protein, we performed competition
experiments in which tetraphenylphosphonium chloride
(TPP) was titrated into a solution containing the preformed
AcrB–R6G complex. In this case, TPP was chosen as a second
ligand to knock oﬀ the bound R6G from AcrB. The absorp-
tion spectra of TPP (from 200 to 600 nm) showed that this
molecule absorbs light at the wavelengths of 224.9, 268.0 and
275.9 nm. At k = 527 nm, which is the excitation wavelength
for R6G, the energy is too low to excite TPP. Thus, TPP
was treated as a non-ﬂuorescent ligand in the ‘‘knock oﬀ’’
experiments. The data revealed that TPP was able to bind
AcrB and replace the bound R6G molecule from the protein
as demonstrated by the release of R6G that resulted in the
reduction of polarization (Fig. 5). This binding assay provides
direct evidence that TPP interferes with the binding of R6G.
However, it is not known that this heterologous displacement
is due to a truly competitive binding or via negative hetero-
tropic allostery between distinct binding sites of the ligands.
We were unable to determine the binding aﬃnity of TPP
through these competition experiments due to precipitation
of the protein at higher TPP concentrations. Regardless, the
titrations demonstrate that R6G is bound speciﬁcally in the
AcrB transporter.
We also tried these competition experiments using erythro-
mycin, which is another AcrB drug, as a second ligand to re-
place the bound R6G from the transporter (not shown). The
data revealed that erythromycin is not capable of knocking
oﬀ the bound R6G, as the polarization of R6G does not
change during titrations. Thus, there is a chance that diﬀerent
class of drugs may bind at diﬀerent sites in AcrB.
The binding of R6G to AcrB was strongly pH-dependent. A
trivial explanation of this result was the pH-dependent alter-ation of charge state in the ligand. However, we found that
there is essentially no change in the emission spectra of free
R6G in the pH range examined in Fig. 4, suggesting that the
electronic arrangement of the protonated and de-protonated
states of R6G are very similar. The pKa of R6G is nearly neu-
tral, with the value equals 7.5 [26] (the pKas of Pf and Cip are
8.1 and 6.1, respectively [27]). At pH < pKa, R6G should exist
in its protonated form. When pH > pKa, this dye should be
predominantly unionized. It is expected that R6G should bind
tighter to the transporter at acidic pH, as it is predominantly in
the positively charged form. However, the reverse case is seen
from the pH dependent data. One possible explanation is that
R6G possesses a large degree of delocalization. It is this large
extent of electron delocalization that makes the chemical prop-
erties of the protonated and de-protonated forms of R6G very
similar. Indeed, it has been reported that the observed octane/
water partition coeﬃcient of R6G remains the same from pH 4
to 11 because of this charge delocalization phenomenon [26].
Judging from the binding isotherms of AcrB in the presence
of 1 lM R6G, these curves maintained the simple hyperbolic
shape and reached saturation at the same AcrB concentration
at diﬀerent pH values (as shown in Fig. 1a). Thus, it is not likely
that altering the pH aﬀects the capacity of binding. Perhaps the
pH eﬀect is related to the protonation state of acidic residues in
the binding pocket: there are several acidic residues in the ligand
binding site of the asymmetric AcrB crystal [12], with Asp276
particularly close to the ligand. The strong pH dependence for
drug binding has been observed as the result of binding of cat-
ionic drugs with the glutamate residue in the EmrE multidrug
transporter [24]. Alternatively, it could involve global confor-
mational changes of the transporter that utilizes the transmem-
brane electrochemical gradient of protons for activity.
Fluorescence polarization assay has been widely used for
studying protein–DNA interactions [19,20,28,29], and lately
for determining aﬃnities of drug binding in transcriptional
regulators [29–31]. To our knowledge, this is the ﬁrst attempt
using this methodology to investigate interaction between
4976 C.-C. Su et al. / FEBS Letters 581 (2007) 4972–4976membrane protein and bound drug. The availability of ﬂuores-
cence polarization to measure aﬃnities of a variety of AcrB
substrates will provide the means for studying the interactions
of other puriﬁed transporters with their substrates in detergent
solutions.
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